BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28842653)

  • 1. Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China.
    An SY; Yang YJ; Hang F; Wang ZM; Fan CM
    Sci Rep; 2017 Aug; 7(1):9506. PubMed ID: 28842653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience.
    Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender Disparities in Clinical Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in the Chinese Han Population: A Cohort Study.
    Wang Y; Zhao HW; Wang CF; Meng QK; Cui CS; Zhang XJ; Zhu Y; Fan CY; Luo DF; Chen BJ; Luan B; Hou AJ
    Heart Lung Circ; 2020 Dec; 29(12):1856-1864. PubMed ID: 32611501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly.
    Liebregts M; Steggerda RC; Vriesendorp PA; van Velzen H; Schinkel AF; Willems R; van Cleemput J; van den Berg MP; Michels M; ten Berg JM
    JACC Cardiovasc Interv; 2016 Mar; 9(5):463-9. PubMed ID: 26965935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.
    Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.
    Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Tomasov P; Adlova R; Bundgaard H; Steggerda R; Ten Berg J; Faber L
    Eur Heart J; 2016 May; 37(19):1517-23. PubMed ID: 26746632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
    Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre.
    Wojtarowicz A; Kornacewicz-Jach Z
    Cardiol J; 2017; 24(2):125-130. PubMed ID: 27734458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Survival After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Experience.
    Fernandes V; Karimianpour A; Rier JD; Shaji S; Mullinax BJ; Wahlquist AH; Nielsen CD
    J Invasive Cardiol; 2021 Oct; 33(10):E769-E776. PubMed ID: 34559674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after alcohol septal ablation versus conservative therapy in obstructive hypertrophic cardiomyopathy.
    Yang YJ; Fan CM; Yuan JQ; Qiao SB; Hu FH; Guo XY; Li YS
    Cardiol J; 2015; 22(6):657-64. PubMed ID: 26100829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.
    Zhu C; Tang B; Cui H; Wang S; Xiao M; Chen Z; Meng Y; Zhao S; Song Y; Yu Q; Wang S
    J Card Surg; 2019 Jul; 34(7):533-540. PubMed ID: 31111576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation.
    Kwon DH; Kapadia SR; Tuzcu EM; Halley CM; Gorodeski EZ; Curtin RJ; Thamilarasan M; Smedira NG; Lytle BW; Lever HM; Desai MY
    JACC Cardiovasc Interv; 2008 Aug; 1(4):432-8. PubMed ID: 19463341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy.
    Liebregts M; Vriesendorp PA; Steggerda RC; Schinkel AF; Balt JC; Ten Cate FJ; Michels M; Ten Berg JM
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):945-952. PubMed ID: 26946355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
    Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL
    Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Safe and Apparently Efficacious But Does Reporting of Aggregate Outcomes Hide Less-Favorable Results, Experienced by a Substantial Proportion of Patients?
    Cooper RM; Shahzad A; McShane J; Stables RH
    J Invasive Cardiol; 2015 Jul; 27(7):301-8. PubMed ID: 26136275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy.
    Balt JC; Wijffels MC; Boersma LV; Wever EF; ten Berg JM
    Heart; 2014 Dec; 100(23):1865-70. PubMed ID: 25073885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Klopotowski M; Chojnowska L; Malek LA; Maczynska R; Kukula K; Demkow M; Witkowski A; Dabrowski M; Karcz M; Baranowski R; Kusmierczyk-Droszcz B; Kruk M; Jamiolkowski J; Kusmierczyk M; Szumowski L; Ruzyllo W
    Clin Res Cardiol; 2010 May; 99(5):285-92. PubMed ID: 20148331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.